Clinical Policy: Vismodegib (Erivedge)
Reference Number: CP.PHAR.273
Effective Date: 08.16
Last Review Date: 05.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Vismodegib (Erivedge®) is a hedgehog pathway inhibitor.

FDA Approved Indication(s)
Erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Erivedge is medically necessary when the following criteria are met:

I. Initial Approval Criteria
A. Basal Cell Carcinoma (must meet all):
   1. Diagnosis of BCC;
   2. Prescribed by or in consultation with an oncologist;
   3. Age ≥ 18 years;
   4. Request meets one of the following (a or b):*
      a. Dose does not exceed 150 mg (one capsule) per day;
      b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   *Prescribed regimen must be FDA-approved or recommended by NCCN

   Approval duration:
   Medicaid/HIM – 6 months
   Commercial – Length of Benefit

B. Medulloblastoma (off-label) (must meet all):
   1. Diagnosis of recurrent medulloblastoma;
   2. Prescribed by or in consultation with an oncologist;
   3. Age ≥ 18 years;
   4. Member has received prior chemotherapy;
   5. Tumor is positive for a sonic hedgehog mutation;
   6. Request meets one of the following (a or b):*
      a. Dose does not exceed 150 mg (one capsule) per day;
b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:**
- Medicaid/HIM – 6 months
- Commercial – Length of Benefit

**C. Other diagnoses/indications**
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I (must meet all):**
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Erivedge for a covered indication and has received this medication for at least 30 days;
2. Member has responded positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
   a. New dose does not exceed 150 mg (one capsule) day;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:**
- Medicaid/HIM – 12 months
- Commercial – Length of Benefit

**B. Other diagnoses/indications (must meet 1 or 2):**
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less); or**
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

**A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies –**
- CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*
- BCC: basal cell carcinoma
- FDA: Food and Drug Administration
NCCN: National Comprehensive Cancer Network

Appendix B: Therapeutic Alternatives
Not applicable.

Appendix C: Contraindications/Boxed Warnings
• Contraindication(s): none reported
• Boxed warning(s): embryo-fetal toxicity

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCC</td>
<td>150 mg PO QD</td>
<td>150 mg/day</td>
</tr>
</tbody>
</table>

VI. Product Availability
Capsules: 150 mg

VII. References

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.PHAR.99 Erivedge and Odomzo. Criteria: removed age restriction and pregnancy safety criteria. Background: added formulations.</td>
<td>06.16</td>
<td>08.16</td>
</tr>
<tr>
<td>Confirmation of pregnancy status added. Approval periods increased from 3/6 to 6/12 months.</td>
<td>07.17</td>
<td>08.17</td>
</tr>
<tr>
<td>2Q 2018 annual review: policies combined for Medicaid and HIM lines of business; added prescriber and age requirement; updated NCCN Compendium supported use in BCC with nodal or distant metastases; removed pregnancy as not an absolute CI per PI; added continuity of care language; references reviewed and updated.</td>
<td>02.08.18</td>
<td>05.18</td>
</tr>
<tr>
<td>2Q 2019 annual review: added Commercial line of business; summarized NCCN and FDA approved uses for improved clarity by removing specific requirements for locally advanced, nodal, or distant metastasis (approach aligns with previously approved corporate policy for Odomzo); references reviewed and updated.</td>
<td>02.04.19</td>
<td>05.19</td>
</tr>
</tbody>
</table>
**Clinical Policy**

**Vismodegib**

---

### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.11.20</td>
<td>05.20</td>
</tr>
</tbody>
</table>

**2Q 2020 annual review:** NCCN recommended use added for medulloblastoma; HIM nonformulary language removed; references reviewed and updated.

---

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.